116 related articles for article (PubMed ID: 38400841)
1. Combined eutexia and amorphization for simultaneous enhancement of dissolution rate of triamterene and hydrochlorothiazide: preparation of orodispersible tablets.
Awad HA; Fetouh MI; Sultan AA; El Maghraby GM
Drug Dev Ind Pharm; 2024 Apr; 50(4):306-319. PubMed ID: 38400841
[TBL] [Abstract][Full Text] [Related]
2. Sucralose as co-crystal co-former for hydrochlorothiazide: development of oral disintegrating tablets.
Arafa MF; El-Gizawy SA; Osman MA; El Maghraby GM
Drug Dev Ind Pharm; 2016 Aug; 42(8):1225-33. PubMed ID: 26555927
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Co-Crystallization of Olmesartan Medoxomil and Hydrochlorothiazide for Enhanced Dissolution Rate in Their Fixed Dose Combination.
Abdelquader MM; Essa EA; El Maghraby GM
AAPS PharmSciTech; 2018 Dec; 20(1):3. PubMed ID: 30560314
[TBL] [Abstract][Full Text] [Related]
4. Preparation of orodispersible tablets of bosentan using xylitol and menthol as dissolution enhancers.
Sakr RM; Abdelaziz AES; Mazyed EA; El Maghraby GM
Sci Rep; 2024 May; 14(1):10680. PubMed ID: 38724608
[TBL] [Abstract][Full Text] [Related]
5. Xylitol as a potential co-crystal co-former for enhancing dissolution rate of felodipine: preparation and evaluation of sublingual tablets.
Arafa MF; El-Gizawy SA; Osman MA; El Maghraby GM
Pharm Dev Technol; 2018 Jun; 23(5):454-463. PubMed ID: 27681386
[TBL] [Abstract][Full Text] [Related]
6. Melting point depression for enhanced dissolution rate of eslicarbazepine acetate.
Dorgham EM; El Maghraby GM; Essa EA; Arafa MF
Drug Dev Ind Pharm; 2022 Dec; 48(12):717-726. PubMed ID: 36546677
[TBL] [Abstract][Full Text] [Related]
7. Co-crystallization for enhanced dissolution rate of bicalutamide: preparation and evaluation of rapidly disintegrating tablets.
Essa EA; Elbasuony AR; Abdelaziz AE; El Maghraby GM
Drug Dev Ind Pharm; 2019 Aug; 45(8):1215-1223. PubMed ID: 30661420
[No Abstract] [Full Text] [Related]
8. Aerosil as a novel co-crystal co-former for improving the dissolution rate of hydrochlorothiazide.
El-Gizawy SA; Osman MA; Arafa MF; El Maghraby GM
Int J Pharm; 2015 Jan; 478(2):773-8. PubMed ID: 25529436
[TBL] [Abstract][Full Text] [Related]
9. Effect of processing methods on xylitol-starch base co-processed adjuvant for orally disintegrating tablet application.
Bin LK; Helaluddin ABM; Islam Sarker MZ; Mandal UK; Gaurav A
Pak J Pharm Sci; 2020 Mar; 33(2):551-559. PubMed ID: 32276897
[TBL] [Abstract][Full Text] [Related]
10. Eutexia for enhanced dissolution rate and anti-inflammatory activity of nonsteroidal anti-inflammatory agents: Caffeine as a melting point modulator.
Alshaikh RA; Essa EA; El Maghraby GM
Int J Pharm; 2019 May; 563():395-405. PubMed ID: 30978486
[TBL] [Abstract][Full Text] [Related]
11. Influence of pH modifiers on the dissolution and stability of hydrochlorothiazide in the bi- and three-layer tablets.
Blatnik SU; Dreu R; Srčič S
Acta Pharm; 2015 Dec; 65(4):383-97. PubMed ID: 26677896
[TBL] [Abstract][Full Text] [Related]
12. A new antihypertensive agent: Maxzide (75 mg triamterene/50 mg hydrochlorothiazide).
Blume CD; Williams RL
Am J Med; 1984 Nov; 77(5A):52-8. PubMed ID: 6388327
[TBL] [Abstract][Full Text] [Related]
13. Amelioration of tableting properties and dissolution rate of naproxen co-grinded with nicotinamide: preparation and characterization of co-grinded mixture.
Khizar N; Abbas N; Ahmed M; Ahmad M; Mustafa Z; Jehangir M; Mohammed Al-Ahmary K; Hussain A; Bukhari NI; Ali I
Drug Dev Ind Pharm; 2024 Jun; 50(6):537-549. PubMed ID: 38771120
[TBL] [Abstract][Full Text] [Related]
14. In vitro/in vivo evaluation of hydrochlorothiazide in experimental hydrochlorothiazide/triamterene combination tablets in beagle dogs.
Ritschel WA; Turkoglu M; Lipps D; Warner A; Sakr A
Arzneimittelforschung; 1991 Mar; 41(3):208-11. PubMed ID: 1867656
[TBL] [Abstract][Full Text] [Related]
15. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
[TBL] [Abstract][Full Text] [Related]
16. Preliminary observations on dissolution and bioavailability of triamterene-hydrochlorothiazide combination products.
Shah VP; Walker MA; Prasad VK; Lin J; Knapp G; Cabana BE
Biopharm Drug Dispos; 1984; 5(1):11-9. PubMed ID: 6704502
[TBL] [Abstract][Full Text] [Related]
17. Bioequivalence study of a new tablet formulation of triamterene and hydrochlorothiazide.
Blume CD; Williams RL; Upton RA; Lin ET; Benet LZ
Am J Med; 1984 Nov; 77(5A):59-61. PubMed ID: 6496560
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles.
Liu Y; Sun C; Hao Y; Jiang T; Zheng L; Wang S
J Pharm Pharm Sci; 2010; 13(4):589-606. PubMed ID: 21486533
[TBL] [Abstract][Full Text] [Related]
19. Development of a Novel Co-processed Excipitient Comprising of Xylitol, Mannitol, Microcrystalline Cellulose, and Crospovidone for the Compounding of Memantine Hydrochloride Orally Disintegrating Tablet.
Hazdi SN; Phang HC; Ng ZQ; Chew YL; Uddin AH; Sarker ZI; Lee SK; Liew KB
Int J Pharm Compd; 2023; 27(6):522-527. PubMed ID: 38100670
[TBL] [Abstract][Full Text] [Related]
20. Co-processing of Atorvastatin and Ezetimibe for Enhanced Dissolution Rate: In Vitro and In Vivo Correlation.
Arafa MF; Alshaikh RA; Abdelquader MM; El Maghraby GM
AAPS PharmSciTech; 2021 Jan; 22(2):59. PubMed ID: 33517486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
